NIH trial success suggests a new treatment option for older, sicker patients
Adults stop anti-rejection drugs after stem-cell transplant reverses sickle cell disease NIH trial success suggests a new treatment option for older, sicker patients
Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of theĀ Journal of the American Medical Association. The trial was conducted at the National Institutes of Health‘s Clinical Center in Bethesda, Maryland, by researchers from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute.
The transplant done in the study reversed sickle cell disease in nearly all the patients. Despite having both donor stem-cells and their own cells in their blood, the patients stopped the immunosuppressant medication without experiencing rejection or graft-versus-host disease, in which donor cells attack the recipient. Both are common, serious side effects of transplants.
“Typically, stem-cell recipients must take immunosuppressants all their lives,” said Matthew Hsieh, M.D., lead author on the paper and staff clinician at NIH. “That the patients who discontinued this medication were able to do so safely points to the stability of the partial transplant regimen.”
Read more . . .
The Latest on: Sickle cell disease
[google_news title=”” keyword=”Sickle cell disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Sickle cell disease
- Exa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell Patientson April 25, 2024 at 11:30 pm
For almost all patients with sickle cell disease, treatment with exagamglogene autotemcel (exa-cel) eliminates vaso-occlusive crises, according to a study published in the April 24 issue of the New ...
- Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapieson April 25, 2024 at 6:38 am
Walgreens Boots Alliance (WBA) expands specialty pharmacy services with dedicated unit for gene and cell therapy. Read more here.
- Researchers publish final results of key clinical trial for gene therapy for sickle cell diseaseon April 25, 2024 at 6:14 am
In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY ...
- CT Up Close: Students with sickle cell disease share key takeaways from visit to NASA space centeron April 25, 2024 at 5:06 am
Last month, about 20 local students with sickle cell disease traveled to NASA’s Goddard Space Center in Maryland to learn more about STEM careers and what they can ...
- CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patientson April 24, 2024 at 11:33 pm
In a landmark study, an international consortium led by researchers at (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the ...
- 10-year-old survivor uses literature to fight sickle cellon April 24, 2024 at 2:16 pm
Cai Stoudemir is a 10-year-old Author and Sickle Cell Survivor from Milwaukee. She wrote this book, Cai hopes to educate kids and adults about the disease.
- 2025 Cell & Gene Therapy Reimbursement Outlookon April 24, 2024 at 1:00 pm
CMS proposed Medicare’s CGT reimbursement policy matches Medicaid’s sickle cell disease policy, forming a unified government approach.
- Alteration of brain network condition could predict painful vaso-occlusive crisis in patients with sickle cell diseaseon April 24, 2024 at 12:16 pm
A new study led by Indiana University School of Medicine researchers has found that a brain network condition called "explosive synchronization" could be the cause of extreme pain crises in people ...
- Tulsa Woman Organizes Event To Support Caregivers, People Living With Sickle Cell Diseaseon April 24, 2024 at 6:50 am
Velvet Brown Watts gave birth to her son who was diagnosed with Sickle Cell Disease. She said it’s been a challenging journey, but now she is working to raise awareness of this blood disorder within ...
- Young New Orleans sickle cell patient is leaving pain behind after a bone marrow transplanton April 22, 2024 at 5:44 am
At only 12 years old, Kelsey Farris already has endured periods of searing pain, endless rounds of medical tests and several lengthy stays at Children’s Hospital in New Orleans. But ...
via Bing News